Co-treatment with mitoxantrone and an anti-LUNX antibody caused suppression of subcutaneous tumor growth as evidenced by a significant reduction in tumor volume when compared with the group treated with mitoxantrone alone (Fig. 6D, E). Here, BPIFA1 is linked to neoplasm.